TIDMFUM
RNS Number : 8992Z
Futura Medical PLC
17 January 2024
Futura Medical plc
("Futura" or the "Company")
Remuneration of Non-Executive Directors and Total Voting
Rights
17 January 2024
Futura Medical plc (AIM: FUM) (the "Company"), the
pharmaceutical company developing innovative sexual health
products, announces the issue of 43,500 new ordinary shares of 0.2
pence each ("Ordinary Shares") in respect of the 2023 remuneration
of its Non-Executive Directors.
Remuneration of Non-Executive Directors
In accordance with the terms of their service agreements, the
Non-Executive Directors receive 25 per cent of their remuneration
in the form of Ordinary Shares which are usually in January
following the period end. For 2023, these were issued at 51.50
pence per share, being the average closing mid-market price of the
last 10 trading days of 2022 (as announced via RNS on 12 January
2023).
The 43,500 new Ordinary Shares shall rank pari passu with the
existing issued Ordinary Shares of the Company and have been issued
to the following Non-Executive Directors:
Director Number of Ordinary Shares issued Total number of ordinary shares Percentage of the Company's
for 2023 remuneration held resulting issued share capital
Jeff Needham 11,617 27,961 0.01%
Andrew Unitt 11,970 38,496 0.01%
In addition, 19,913 shares have been issued to John Clarke. John
Clarke was a Non-Executive Director until July 2023 and these
shares represent 25 per cent of his pro-rata remuneration for the
period January to July 2023 in accordance with his service
agreement.
The shares element of the Non-Executive Directors' remuneration
for 2024 will be awarded at 27.10 pence per Ordinary Share, being
the average closing mid-market price of the last 10 trading days of
2023. The Non-Executive Directors will receive these shares in
January 2025.
Total Voting Rights
Application has been made to the London Stock Exchange and it is
anticipated that trading of the new Ordinary Shares will commence
on AIM at 8:00am on 22 January 2024.
Immediately following the above issue, the Company will have
301,449,451 ordinary shares in issue, each carrying one voting
right. Since the Company currently holds no shares in treasury, the
total number of voting rights in the Company is therefore
301,449,541 and this figure may be used by Shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change in their
interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Further details are contained within the notifications below,
made in accordance with Article 19 of the EU Market Abuse
Regulation 596/2014. Full details of the Non-Executive Directors'
remuneration will be included in the Company's Annual Report &
Accounts.
S
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.Futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker /Benjamin Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin / Jonathan Edwards / Elena Bates
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing innovative products based on its proprietary,
transdermal DermaSys(R) technology.
MED3000, the Company's breakthrough treatment for erectile
dysfunction ("ED") has a unique evaporative mode of action and is
clinically proven as an effective topical treatment for adult men
with ED, with a key claim of "Helps you get an erection within 10
minutes". Eroxon(R) is available Over the Counter ("OTC") without a
doctor's prescription. www.eroxon.com .
MED3000 is being manufactured and commercialised under the brand
name Eroxon(R) and has been granted marketing authorisation by the
FDA in the US, CE marked in Europe, UKCA marked in the UK and is
gaining regulatory approval in a growing number of countries across
the world. Futura has commercial agreements with Haleon for the US
market and Cooper Consumer Health for Europe.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange. www.futuramedical.com
.
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Jeff Needham
------------------------------ -----------------------------------
Reason for the notification
2
-------------------------------------------------------------------
a) Position/status Director/ PDMR
------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------ -----------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Futura Medical plc
------------------------------ -----------------------------------
b) LEI 21380053QLT46UNV2303
------------------------------ -----------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the
financial instrument, Ordinary shares of 0.2p each
type of instrument
GB0033278473
Identification code
------------------------------ -----------------------------------
b) Nature of the transaction Issue of shares
------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
51.50 pence 11,617
----------
------------------------------ -----------------------------------
d) Aggregated information
- Aggregated volume
Not applicable
- Price
------------------------------ -----------------------------------
e) Date of the transaction 16 January 2024
------------------------------ -----------------------------------
f) Place of the transaction Outside of trading venue
------------------------------ -----------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Andrew Unitt
------------------------------ -----------------------------------
Reason for the notification
2
-------------------------------------------------------------------
a) Position/status Director/ PDMR
------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------ -----------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Futura Medical plc
------------------------------ -----------------------------------
b) LEI 21380053QLT46UNV2303
------------------------------ -----------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the
financial instrument, Ordinary shares of 0.2p each
type of instrument
GB0033278473
Identification code
------------------------------ -----------------------------------
b) Nature of the transaction Issue of shares
------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
51.50 pence 11,970
----------
------------------------------ -----------------------------------
d) Aggregated information
- Aggregated volume
Not applicable
- Price
------------------------------ -----------------------------------
e) Date of the transaction 16 January 2024
------------------------------ -----------------------------------
f) Place of the transaction Outside of trading venue
------------------------------ -----------------------------------
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRGPUAUGUPCGMQ
(END) Dow Jones Newswires
January 17, 2024 02:00 ET (07:00 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2023 to Apr 2024
